AI to play significant role in RTSM and IRT systems, says Oracle

Artificial intelligence will play a significant role in the development of randomization and supply chain management technologies, according to Oracle, which uses embedded AI in its own RTSM system.

Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, shared her take on the trial technology market this week, telling Clinical Insider AI makes trial supply management more efficient.

“We expect that AI will play a significant role in the future of RTSM and IRT systems by improving prediction, optimization, and automation. For example, AI can anticipate drug supply needs based on recruitment trends, reduce overages and waste, or dynamically adjust randomization algorithms in adaptive trials.

“At Oracle, we prioritize embedded AI-driven rule creation and operational insights for our RTSM to help sponsors build smarter protocols, reduce manual interventions, and make data-informed decisions throughout the trial life cycle,” she said.

And making randomization and supply management more straightforward is vital for companies working in the technology space, according to Verma.

“It is a competitive and rapidly evolving space. Established players — like Oracle — have long delivered robust solutions, while newer entrants and niche vendors continue to emerge.

“What differentiates true leaders today” she continued, “is the ability to offer customer-initiated builds, dramatically increase quality, reduce setup times, increase flexibility, and offer cloud-native, interoperable systems that can scale to meet the demands of increasingly complex trial designs.”

Vendor agnostic

Earlier this year, Oracle announced several vendor-agnostic interoperability advancements to its RTSM systems, explaining the advances enable drug pooling and supply management automation across multiple trials.

The approach is designed with the wider clinical trials ecosystem — sponsors, CROs, and sites — in mind, according to Verma, who cited hospitals as an example.

“In this environment, hospitals can launch trials at the point of care, identify eligible patients in real time, and continuously capture real-world data — driving smarter research, better treatment decisions, higher quality, and the faster, safer delivery of new therapeutics.”

Learn more about IRT and RTSM at our upcoming conference.

DepositPhotos/kamome2535